Search

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Jan 15 2020 Posted in Meeting reports

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

New GFI1B variants in bleeding and platelet disorders

Jun 12 2015 Posted in Press releases

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Curriculum-Exam Committee

Current committee members
Jose Tomás Navarro Ferrando, Spain (Chair)
Marielle Wondergem, The Netherlands (Vice-Chair and Progress test lead)
Alicia Rovó, Switzerland (Representative, Swiss Society)
Regular members
Gunnar Birgegård, Sweden
Roza Chaireti, Sweden
Carlos Fernández de Larrea, Spain
Mahesh Prahladan, United Kingdom
Ulla Wartiovaara-Kautto, Finland
AimTo promote harmonization in hematology training…

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

EHA donates €250,000 to Médecins Sans Frontières

Mar 30 2022 Posted in EHA's actions for Ukraine

The EHA Board is actively implementing support actions to hematologists and hematology patients in Ukraine and to those who are forced to leave the country.